Blocking knee blood vessels versus a sham procedure for knee osteoarthritis pain
Compares genicular artery embolization with a sham procedure for knee osteoarthritis pain.
Key facts
- Who runs it
- University of Utah
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Registry title
- Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 40 people, planned
- Started
- 1 Jul 2026
- Expected to end
- 31 Aug 2028
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- Genicular Artery Embolization
- Lipiodol
- Simple angiogram
- Record updated
- 30 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with painful knee osteoarthritis that has not improved with non-surgical care. It compares a procedure that briefly blocks knee arteries (GAE) with a sham procedure.
- Age
- 40 to 80 years
- Sex
- All sexes
- Disease stage
- Knee osteoarthritis grade 2-4 on standing knee X-rays (Kellgren-Lawrence scale). Knee pain for more than 6 months, scored 4 or more on a pain scale (VAS).
- Earlier treatment
- Pain must not have improved with non-surgical care, such as rest, physical therapy, NSAIDs, acetaminophen or injections. People must refuse steroid injection into the knee. No steroid injection in that knee within 3 months. No prior surgery on that knee, except diagnostic arthroscopy.
- Biomarker or test result
- Kidney filtration (GFR) must not be below 60 mL/min/1.73 m².
Main reasons for not taking part
- Active cancer or active infection of the affected knee
- Rheumatoid arthritis, other arthritis of this type, or fibromyalgia
- Pregnancy or expected pregnancy
- Severe allergy to contrast dye, asthma, or past kidney injury
- Body weight over 400 lbs (181 kg), or plans for knee replacement in the next year
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Patients aged 40-80
- Bilateral or unilateral knee pain attributed to osteoarthritis (treat the knee with greater pain-if equal, patient chooses)
- Grade 2-4 osteoarthritis on standing weight-bearing knee radiographs per the Kellgren-Lawrence grading scale
- Knee pain > 6 months, refractory to conservative non-operative management, and scored ≥ 4 on Visual Analog Scale (VAS) (e.g., rest, activity modification, weight control, bracing, supervised physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, oral opiates, intra-articular hyaluronic acid, PRP, stem cells, and/or oral/injectable corticosteroids)
- Refusal of intra-articular corticosteroid injection
Who cannot take part
- Corticosteroid injection of the affected knee within 3 months of enrollment
- Previous surgery of the affected knee (e.g., meniscus repair, meniscectomy, anterior cruciate ligament (ACL)/posterior cruciate ligament (PCL) reconstruction, chondroplasty, microfracture, loose-body removal, synovectomy, lateral release, patellar/quadriceps tendon repair, total or partial knee replacement, osteotomy, cartilage transplant), except diagnostic arthroscopy
- Long-acting corticosteroid use within 6 months (3 months for short-acting)
- Suicide attempt or suicidal behavior within 30 days before screening
- Active malignancy
- Active infection of the affected knee
- Peripheral arterial disease of the treated extremity (Rutherford Grade 2 or greater)
- Type 1 diabetes mellitus
- History of reaction to contrast media, bronchial asthma, or allergic disorders
- History of hypersensitivity to gadolinium-based contrast agents (GBCAs)
- Major depressive disorder within 2 years before screening
- Other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder)
- Any other condition, unwillingness, or inability that, in the investigator's opinion, could jeopardize the subject's safety or protocol compliance
- GFR < 60 mL/min/1.73 m²
- Rheumatoid arthritis or other seronegative arthropathy
- Grade 0-1 osteoarthritis per Kellgren-Lawrence grading scale of the affected knee
- Pregnancy or expected pregnancy
- Anaphylactic reaction to iodinated contrast
- Moderate to severe pain in other ipsilateral lower-limb joints (ankle, hip) with VAS > 4
- Body weight > 400 lbs (unsafe for angiography)
- History or other evidence of acute kidney injury (AKI)
- Chronic widespread generalized pain >4 on VAS pain scale, including neuropathic pain
- Diagnosis of fibromyalgia
- Considering total knee replacement in the next year
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 80 years old?
Where in United States
- University of UtahSalt Lake City, United StatesContact: Osman Ahmed, MDTaking people
About the trial
What the trial wants to find out
Genicular Artery Embolization for Reducing Pain in Symptomatic Knee Osteoarthritis: A Pilot Randomized Sham-Controlled Study (SHAM-PAIN) is a NIH-NIAMS funded project designed to assess enrollment feasibility and detect any differences between GAE and a similar sham intervention in reducing KOA-related pain at 3 months as measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscore. Additionally, this study aims to determine the magnitude of difference in pain response between GAE and sham to adequately power a larger, more definitive randomized sham-controlled trial (RCT). The influence of psychosocial and psychocognitive factors, changes in analgesic use, and conditions of knee joint cartilage and effusion will similarly be explored to determine their impacts on perceived pain response to GAE.
The 2 groups in the trial
- GAE ArmTreatment being tested
In this study, GAE is performed using the Lipiojoint technique described by Sapoval et al. This method utilizes a 3:1 emulsion of Lipiodol® (a transient embolic agent that penetrates distally to about 30 microns) and Optiray® to target the genicular arteries supplying areas of synovial hypervascularity and neo-angiogenesis. The embolic effect is temporary-lasting roughly 10 minutes-after which angiographic imaging shows resolution of the embolization with no damage to the surrounding skin, tendon, or bone. The endpoint of the procedure is to achieve complete stasis in the targeted vessels. 20 participants will be randomly allocated to this arm.
Treatment: Genicular Artery Embolization, Lipiodol, and Simple angiogram
- Sham ArmSham treatment, for comparison
Participants assigned to the sham group undergo a similar preparatory process, including angiography and catheterization of all genicular arteries. However, no embolic agent is administered. Instead, after performing selective angiograms, these participants do not receive any embolization. 20 participants will be randomly allocated to this arm.
Treatment: Simple angiogram
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Genicular Artery Embolization for Reducing Pain in Symptomatic Knee Osteoarthritis: A Pilot Randomized Sham-Controlled Study
- Plain-language title
- Blocking knee blood vessels versus a sham procedure for knee osteoarthritis painGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06859164, who can take part
- Record updated
- 30 October 2026